World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
109
Citations
57440
World Ranking
5683
National Ranking
3060

Overview

W. Fraser Symmans is a researcher affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their primary fields of study are in Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on Cancer Research and Oncology. The scientist's work also intersects with Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine, and Molecular Biology.

The main research topics covered by W. Fraser Symmans include:

  • Breast Cancer Treatment Studies
  • Cancer Genomics and Diagnostics
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • Cancer Cells and Metastasis

W. Fraser Symmans has published extensively, with notable recent papers including:

  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update, 2020, Journal of Clinical Oncology
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline, 2021, Journal of Clinical Oncology
  • Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer, 2020, JAMA Oncology
  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, 2023, Journal of Clinical Oncology
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update, 2020, Archives of Pathology & Laboratory Medicine

The researcher frequently collaborates with several co-authors, including:

  • Laura J. Esserman
  • Christina Yau
  • Angela DeMichele
  • Douglas Yee
  • Nola M. Hylton

W. Fraser Symmans often publishes in these journals:

  • Cancer Research
  • Journal of Clinical Oncology
  • npj Breast Cancer
  • Clinical Cancer Research
  • JAMA Oncology

Best Publications

  • Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

    Cornelia Liedtke;Chafika Mazouni;Kenneth R. Hess;Fabrice André

  • The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

    R. Salgado;C. Denkert;S. Demaria;N. Sirtaine

  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

    Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim

  • Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

    W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan

  • Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial

    Judy C. Boughey;Vera J. Suman;Elizabeth A. Mittendorf;Gretchen M. Ahrendt

  • The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai

  • An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

    Katherine Stemke-Hale;Ana Maria Gonzalez-Angulo;Ana Lluch;Richard M. Neve

  • The Microarray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models

    Leming Shi;Gregory Campbell;Wendell D. Jones;Fabien Campagne

  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

    Kimberly H. Allison;M. Elizabeth H. Hammond;Mitchell Dowsett;Shannon E. McKernin

  • The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

    Jeffrey S. Ross;Jeffrey S. Ross;Jonathan A. Fletcher;Gerald P. Linette;Gerald P. Linette;James Stec

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

    Hiroko Masuda;Keith A. Baggerly;Ying Wang;Ya Zhang

  • Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

    Sibylle Loibl;Joyce O'Shaughnessy;Michael Untch;William M Sikov

  • A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

    Christos Hatzis;Lajos Pusztai;Vicente Valero;Daniel J. Booser

  • Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

    M. Ayers;W.F. Symmans;J. Stec;A.I. Damokosh

  • Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

    Luca Gianni;Milvia Zambetti;Kim Clark;Joffre Baker

  • An International Ki67 Reproducibility Study

    Mei Yin C Polley;Samuel C Y Leung;Lisa M. McShane;Dongxia Gao

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

    Jong-Ho Cha;Wen-Hao Yang;Weiya Xia;Yongkun Wei

  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

    Larissa A. Korde;Mark R. Somerfield;Lisa A. Carey;Jennie R. Crews

Frequent Co-Authors

Lajos Pusztai
Lajos Pusztai Yale University
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Laura J. Esserman
Laura J. Esserman University of California, San Francisco
Vicente Valero
Vicente Valero The University of Texas MD Anderson Cancer Center
Henry Mark Kuerer
Henry Mark Kuerer The University of Texas MD Anderson Cancer Center
Christina Yau
Christina Yau University of California, San Francisco
Laura J. van't Veer
Laura J. van't Veer University of California, San Francisco
Jeffrey S. Ross
Jeffrey S. Ross Foundation Medicine
Judy C. Boughey
Judy C. Boughey Mayo Clinic
Claudine Isaacs
Claudine Isaacs Georgetown University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up a wide range of flexible, online healthcare degrees. For those interested in mental health, psych nurse practitioner programs offer a clinical pathway to specialize in psychiatric care, supporting diverse patient populations with mental health needs.

Beyond clinical roles, a degree in healthcare administration is crucial for those aspiring to leadership or management positions in hospitals, clinics, or public health organizations. Understanding healthcare administration degree cost is important for students seeking affordable education options. Additionally, for those looking to advance further, programs offering the cheapest master’s in healthcare administration provide advanced skills without the high tuition costs often associated with graduate education.

Nursing professionals aiming for the highest clinical practice roles should consider online Doctor of Nursing Practice (DNP) options. Finding the most affordable online dnp programs can help reduce financial barriers while maximizing career progression opportunities.

Best Scientists Citing W. Fraser Symmans

Trending Scientists